Capstone Therapeutics Corporation announced it has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes totaling up to $10.9 million. The agreement limits the investor's ownership to a maximum of 9.99% of outstanding common stock. Proceeds from future stock sales may be used to redeem amounts under the notes. The company plans to register shares issuable upon conversion of the notes for resale.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-101673), on October 23, 2025, and is solely responsible for the information contained therein.